Human immunodeficiency virus (HIV)- and Non-HIV-associated immunosuppression and risk of cervical neoplasia

Michael J. Silverberg, Wendy A. Leyden, Aileen Chi, Steven Gregorich, Megan J. Huchko, Shalini Kulasingam, Miriam Kuppermann, Anna Seto, Karen K. Smith-Mccune, George F. Sawaya

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

OBJECTIVE:To estimate the risk of cervical intraepithelial neoplasia grade 2, 2-3, 3, adenocarcinoma in situ, or cancer (CIN 2 or worse) among women with human immunodeficiency virus (HIV)- and non-HIV-associated immunosuppression.METHODS:We performed a case-control study of 20,146 women with incident CIN 2 or worse and 5:1 age-matched, incidence-density selected women in a control group (n=100,144) enrolled in an integrated health care system from 1996 to 2014. Adjusted rate ratios (RRs) from conditional logistic regression were obtained for HIV status (stratified by CD4+ T-cells), solid organ transplant history, and immunosuppressive medication use.RESULTS:Risk of CIN 2 or worse was increased among women with HIV (n=36 women in the case group and 79 women in the control group; adjusted RR 2.0, 95% CI 1.3-3.0) compared with those without HIV and in solid organ transplant recipients (n=51 women in the case group and 68 women in the control group; RR 3.3, 95% CI 2.3-4.8) compared with women without a prior transplant. The highest risks were among women with HIV and less than 200 CD4+ T-cells/microliter (n=9 women in the case group and eight women in the control group; RR 5.6, 95% CI 2.1-14.7) compared with those without HIV and in solid organ transplant recipients prescribed three or greater immunosuppressive medication classes (n=32 women in the case group and 33 women in the control group; RR 4.1, 95% CI 2.5-6.8) compared with women without a prior transplant and zero medication classes. No increased risks were observed for women with HIV and 500 or greater CD4+ T-cells/microliter (n=9 women in the case group and 43 women in the control group; RR 0.8, 95% CI 0.4-1.7) compared with those without HIV or women without prior solid organ transplantation prescribed two or fewer immunosuppressive medication classes (n=1,262 women in the case group and 6,100 women in the control group; RR 0.95, 95% CI 0.89-1.01) compared with women without and a prior transplant and zero medication classes.CONCLUSION:Risk of CIN 2 or worse is increased in women with a prior solid organ transplant or who have HIV and CD4+ cells/microliter less than 500 but not in women with HIV and higher CD4+ levels or in women without a prior solid organ transplant but who are prescribed only one or two immunosuppressive medication classes.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalObstetrics and gynecology
Volume131
Issue number1
DOIs
StatePublished - Jan 1 2018

Bibliographical note

Funding Information:
Supported by the National Cancer Institute (R01CA169093).

Publisher Copyright:
© 2017 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.

Fingerprint Dive into the research topics of 'Human immunodeficiency virus (HIV)- and Non-HIV-associated immunosuppression and risk of cervical neoplasia'. Together they form a unique fingerprint.

Cite this